Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;3(3):10.4155/cli.12.155.
doi: 10.4155/cli.12.155.

HIV PrEP Trials: The Road to Success

Melanie R Nicol  1 , Jessica L Adams  2 , Angela Dm Kashuba  3
Affiliations

HIV PrEP Trials: The Road to Success

Melanie R Nicol et al. Clin Investig (Lond). 2013 Mar.

Abstract

The global HIV epidemic cannot be controlled by current treatment or prevention strategies. Pre-exposure prophylaxis (PrEP) using antiretrovirals is a promising approach to curbing the spread of HIV transmission. Recently, four clinical trials demonstrated favorable results when antiretroviral PrEP was administered topically or orally. However, two additional trials were unable to demonstrate a benefit, indicating that further study is required to define the populations and conditions under which PrEP will be effective. Adherence is highly correlated with protection, yet the exact level of adherence required is unknown. Future studies may require increased drug exposure testing and more objective methods to monitor adherence in real-time. Although the development of drug resistance in the PrEP trials has been low, it remains a concern, as therapeutic options could be compromised for those who seroconvert while on PrEP.

Keywords: HIV; adherence; prevention; prophylaxis; tenofovir.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS medicine. 2008;5(2):e28. - PMC - PubMed
    1. Parikh UM, Dobard C, Sharma S, et al. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol. 2009;83(20):10358–10365. - PMC - PubMed
    1. Denton PW, Estes JD, Sun Z, et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS medicine. 2008;5(1):e16. - PMC - PubMed
    1. Cranage M, Sharpe S, Herrera C, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS medicine. 2008;5(8):e157. - PMC - PubMed
    1. Hawkins T, Veikley W, St Claire RL, 3rd, Guyer B, Clark N, Kearney BP. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr. 2005;39(4):406–411. - PubMed

Websites

    1. UNAIDS. [[accessed 28 Sept 2012].];Global HIV/AIDS Response-Progress Report. Available at : http://www.unaids.org/en/resources/publications/2011/name,64437,en.asp.
    1. Microbicide Trials Network. MTN statement on decision to discontinue use of tenofovir gel in VOICE, a major HIV prevention study in women. [[accessed 23 Sep 2012].];Immediate press release. 2011 Nov 25; Available at: http://www.mtnstopshiv.org/node/3909.
    1. FACTS Consortium. [[accessed 23 Sep 2012].];FACTS 001 Study Design. Available at: http://factsconsortium.wordpress.com/facts-001-study/facts-001-study-des...
    1. [[accessed 23 Sep 2012].];CAPRISA 008 Executive Summary. CAPRISA Website. Available from: http://www.caprisa.org/
    1. MTN-008. [[accessed 23 Sep 2012].];Microbicide Trials Network Studies. Available from: http://www.mtnstopshiv.org/studies/1637.

LinkOut - more resources